Content Type: Article

  • Chambers & Partners | Doing Business In… 2022

    ARTICLE

    Chambers & Partners | Doing Business In… 2022

    August 2022

    Read time: 3 min

    Key takeaways
    Overview

    The fourth edition of Chambers Global Practice Guides: Doing Business In… has been published at a time when the world’s economy is facing many uncertainties. The direct effects of the COVID-19 pandemic have now faded, although not entirely. Restrictions on travelling to certain countries remain, and China recently locked down entire cities, provoking a shortage of materials on the global markets.

    Despite all the chaos the world experienced in the past two years, the global economy did not collapse as could have been expected. The spectacular economic downturn that occurred in the first half of 2020 was followed by a rebound in the second half of the year. The World Bank now forecasts an overall increase in economic growth for 2021 of 5.7%, although the pace of the recovery may substantially differ in the various regions of the world.

    The guide, co-edited by McDermott partners Jacques Buhart and Nicolas Lafont, provides the latest legal information on restrictions to foreign investments, corporate vehicles, employment law, tax law, competition law, intellectual property (IP), data protection and upcoming legal reforms.

    In depth

    Doing Business in France

    Authors: Laurent Ayache, Jacques Buhart, Nicolas Lafont, Jilali Maazouz, Laura Morelli, Sabine Naugès, Romain Perray, Frédéric Pradelles and Antoine Vergnat

    France is a civil law jurisdiction where most laws are codified. In the administrative law sphere, case law is paramount as legal precedents are established by judges. Judges also have an important role to play in judicial matters, in the sense that they interpret and apply the law; they do not, however, create new laws. Read more…

    Doing Business in the USA

    Authors: David Grimes and G. N. Smith Alpert

    The US legal system is composed of several coexisting layers of laws that work in concert. As a federation of states, the District of Columbia and several self-governing territories, the USA has two primary levels of legal systems that exist in parallel: (i) the federal government that establishes laws for all of the USA and its people; and (ii) the state governments that govern their respective geographical area and residents. Read more…

    Authors

    Laurent Ayache

    Partner

    Paris

    Jilali Maazouz

    Partner

    Paris

    Sabine Naugès

    Partner

    Paris

    Smith Alpert

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • New York Employment Update: Upcoming Windows to Claim Damages as a Result of Certain Sexual Offenses

    New York Employment Update: Upcoming Windows to Claim Damages as a Result of Certain Sexual Offenses

    ARTICLE / CLIENT ALERT

    New York Employment Update: Upcoming Windows to Claim Damages as a Result of Certain Sexual Offenses

    August 8, 2022

    Read time: 4 min

    Key takeaways
    Overview

    New York Governor Hochul signed the Adult Survivors Act [1] (the “Act”) into law. The Act creates a one-year window, starting on Nov. 24, 2022 and ending on Nov. 24, 2023, in which individuals who claim to be victims of certain sexual offenses, as defined in the New York Penal Law, may assert civil claims for physical, psychological or other injuries or conditions suffered as a result of the sexual offense. The Act only creates an exception for otherwise time-barred claims predicated on a sexual offense, such as: sexual misconduct, rape, criminal sexual acts, forcible touching, persistent sexual abuse, sexual abuse, aggravated sexual abuse, sexually motivated felonies, predatory sexual assault and incest.[2] The Act’s exception applies only where the victim was 18 years of age or older at the time of the alleged sexual offense.

    The Act permits individuals to file a civil suit not only against the individual actor who committed the sexual offense, but also against any persons or groups whose “intentional or negligent acts or omissions” caused an injury or condition. Employers may, therefore, be sued where there is a nexus between a sexual offense against the individual and the employment relationship.

    The Act is modeled after the New York Child Victims Act, which created a similar window for the revival of time-barred abuse claims for victims under the age of 18. According to the Office of Court Administration, the lookback window under the Child Victims Act (which was extended an additional year because of the pandemic), resulted in over 10,000 new lawsuit filings. We expect that there will similarly be a wave of cases filed under the Adult Survivors Act, potentially from decades ago.

    New York City employers should also be aware that the City recently amended its Victims of Gender-Motivated Violence Protection Act (the “VGMVPA”) to include a window for any individual who claims to be a victim of a gender-motivated violent crime to assert civil claims against any party that “commit[ted], direct[ed], enable[d], participate[d] in, or conspire[d] in the commission of a crime of violence motivated by gender.” The VGMVPA window will open on March 1, 2023 and close on March 1, 2025. New York City employers may face liability under the VGMVPA where the employer can be said to have “enabled” the crime to occur. This two-year revival window may result in additional litigation against individuals and institutions, including employers.

    Authored by Mark E. Brossman, Ronald E. Richman, Max Garfield, Scott Gold, Donna Lazarus and Victor Haas.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] See S. 66A, 2021-2022 Leg. Sess. (N.Y. May 24, 2022), available here.

    [2] See N.Y. Penal Law §§ 130.00 et seq., 255.26-27 (Consol. 2022).


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2022 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

     

    In depth
    Authors

    Mark E. Brossman

    Partner

    New York – 919 Third Avenue

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    Max Garfield

    Partner

    New York – 919 Third Avenue

    Donna K. Lazarus

    Partner

    New York – 919 Third Avenue

    More insights

  • Healthcare Regulatory Check-up | July 2022

    Healthcare Regulatory Check-up | July 2022

    ARTICLE / REPORT

    Healthcare Regulatory Check-up | July 2022

    August, 2022

    Read time: 3 min

    Overview

    This issue of McDermott’s Healthcare Regulatory Check-Up highlights significant activity between June 21 and July 20, 2022. During this period, the Supreme Court of the United States overturned Roe v. Wade, which historically recognized the constitutional right to abortion, in Dobbs v. Jackson Women’s Health Organization. This decision has legal implications for virtually all healthcare organizations. The Supreme Court also upheld the US Department of Health & Human Services (HHS) regulations regarding the disproportionate share hospital (DSH) payment formula, finding that individuals “entitled to Medicare Part A benefits” are all individuals qualifying for the program and not just those whose hospital bills were actually paid by Medicare. This issue also reviews several criminal and civil enforcement actions related to Anti-Kickback Statute (AKS) and beneficiary inducement issues, as well as false claims allegations.

    In addition to examining recent Office of Inspector General (OIG) advisory opinions, we offer an update on the OIG’s Special Fraud Alert providing guidance on telemedicine arrangements and OIG’s Annual Health Care Fraud and Abuse Control Program Report. We also examine recently published Centers for Medicare & Medicaid Services (CMS) rules and guidance regarding innovation models, the Clinical Laboratory Improvement Amendments of 1998 (CLIA) regulations, and long-term care facilities requirements.

    In depth
    Tabs

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Monica Wallace

    Partner

    Chicago

    Caroline Reignley

    Partner

    Washington, DC

    More insights
    Endnotes

  • HHS Issues Proposed Rule Under Section 1557 of the Affordable Care Act: Nondiscrimination in Health Programs and Activities

    HHS Issues Proposed Rule Under Section 1557 of the Affordable Care Act: Nondiscrimination in Health Programs and Activities

    ARTICLE / CLIENT ALERT

    HHS Issues Proposed Rule Under Section 1557 of the Affordable Care Act: Nondiscrimination in Health Programs and Activities

    August 5, 2022

    Read time: 29 min

    Key takeaways
    Overview

    On August 4, 2022, the US Department of Health and Human Services (HHS) issued a Notice of Proposed Rulemaking (NPRM or proposed rule) to reinterpret section 1557 of the Affordable Care Act (ACA), which prohibits discrimination on the basis of race, color, national origin, sex, age or disability in a health program or activity, any part of which is receiving federal financial assistance. The proposed rule restores and strengthens certain civil right protections under federally funded health programs and HHS programs which were limited following the 2020 Trump-era version of the rule, specifically regarding discrimination on the basis of sex, including sexual orientation and gender identity, and returns certain protections for individuals with limited English proficiency (LEP). Additionally, the proposed rule bolsters protections against discrimination in healthcare by clarifying that funds received under several federal healthcare programs, including Medicare Part B, are included in the definition of federal financial assistance under the law. As such, under the proposed rule, the list of entities expected to comply with the nondiscrimination measures outlined in Section 1557 of the ACA is significantly expanded, in many ways aligning with the 2016 Obama-era version of the rule. The NPRM also proposes to expand the applicability of the post-Bostock interpretation of “on the basis of sex” to Medicaid, Children’s Health Insurance Programs (CHIP) and Programs of All-Inclusive Care for the Elderly (PACE). For now, portions of the 2020 Final Rule not discordant with Bostock continue to apply.

    In depth

    Background

    Section 1557 of the ACA prohibits any healthcare program or activity, any part of which is receiving federal financial assistance, from discrimination in specific health programs or activities based on race, color, national origin, sex, age and disability. On May 18, 2016, during the Obama administration, HHS originally sought to implement this prohibition in a Final Rule by announcing its interpretation that the statutory provision of discrimination “on the basis of sex” included, among other things, discrimination based on sex stereotyping, gender expression, gender identity and termination of pregnancy. The 2016 Final Rule also set forth obligations to provide certain language assistance to LEP individuals and auxiliary aids and services for individuals with disabilities.

    In 2020, during the Trump administration, HHS revised the 2016 Final Rule, the result of which was the elimination of many protections outlined in 2016, particularly those protections related to gender identity, gender expression, sex stereotyping and termination of pregnancy. The 2020 Final Rule declined altogether to put forth a definition of “on the basis of sex” as used in the ACA. (See our client alert, “HHS finalizes anti-discrimination revisions to ACA Section 1557“).

    On August 4, 2022, HHS issued an NPRM which proposes to restore and strengthen civil right protections under federally funded health programs and HHS programs, which protections were limited following the 2020 version of the rule. The NPRM appears to be the culmination of an executive order issued by the Biden administration and an Equity Action Plan issued by HHS.

    Scope of Section 1557 and Definition of “Covered Entity”

    The prohibition under Section 1557 of the ACA applies to certain “covered entities.” In the 2016 Final Rule, HHS defined covered entity as one that operates a health program or activity, any part of which receives federal financial assistance through HHS (e.g., Medicare, Medicaid; CHIP). In the 2020 Final Rule, HHS clarified that the definition of covered entity included any health program or activity receiving federal funds from HHS, any program or activity administered under Title I of the ACA, and health insurance marketplace participants.

    Under the newly proposed rule, HHS clarifies that the scope of Section 1557 should apply broadly to health programs or activities, including providing, administering or assisting persons with health-related services or insurance; providing pharmaceutical, clinical or medical care; engaging in health research; or providing health education for healthcare professionals or others. HHS elucidates its intended breadth by listing certain entities that would be captured by the enlarged scope, including state and local health agencies, hospitals, health clinics, health insurance issuers, physician practices, community-based healthcare providers, nursing facilities, residential or community-based treatment facilities, or similar entities or combinations, though not intending this to be an exhaustive list. Noticeably missing from this list are employer-sponsored group health plans.

    Under the revised definition of “covered entity,” those that would be subject to the scope of Section 1557 under the NPRM include: (1) recipients of federal assistance, (2) HHS and (3) entities established under Title I of the ACA. “Federal financial assistance” will include any grant, loan, credit, subsidy, contract or other arrangement by which the federal government provides assistance. The proposed definition of covered entities is intended to be expansive in order to capture “all of the operations of any entity principally engaged in the provision or administration of health projects, enterprises, ventures, or undertakings.” This would include, for example, group health insurance issuers and a third-party administrator’s services provided to a self-insured group health plan. The NPRM further explains that the more expansive definition more accurately reflects Congress’s intent that Section 1557 should apply broadly to programs of health insurance, because it was passed as part of the ACA—a law predominantly intended to regulate health insurance.

    Change in Interpretation—Medicare Part B Meets the Definition of Federal Financial Assistance

    The NPRM announces HHS’s position that funds received under Medicare Part B are included within the definition of federal financial assistance for the purpose of coverage under the federal civil rights statutes enforced by HHS, specifically Title VI of the Civil Rights Act of 1964, Section 504 of the Rehabilitation Act of 1973, Title IX of the Education Amendments of 1972, the Age Discrimination Act of 1975 and Section 1557 of the ACA. This is because Part B funds are intended to subsidize healthcare providers and suppliers for the health services and supplies rendered to program beneficiaries. In making this proclamation, HHS reverses the position it has held for nearly 40 years, but it explains its reasoning through a detailed discussion of the evolution of Medicare Part B. HHS also notes that funds received under Medicare Part A have long been considered federal financial assistance, and because Medicare Part A and Medicare Part B are fundamentally similar (e.g., both are federal programs under which providers agree to conditions of participation or coverage in exchange for receiving federal payments for their services to eligible enrolled individuals), the rationale for excluding Medicare Part B funds from the definition of federal financial assistance is not consistent with the purpose and operation of the program.

    Revisions to Prohibition on Discrimination Against Limited English Proficient (LEP) Individuals

    The NPRM proposes language relating to Section 1557’s prohibition on national origin discrimination as applied to LEP individuals in covered health programs and activities. In the NPRM, HHS recognizes that covered entities may violate this prohibition by failing to take reasonable steps to provide meaningful access to LEP individuals, such as providing free and effective language assistance services. To encourage providing such services, covered entities will be required to take reasonable steps toward providing meaningful access to language assistance services (e.g., interpreter and translation services) to LEP individuals “eligible to be served or likely to be directly affected” by its health programs and activities. This is a slight revision to the language in the 2016 Final Rule, which required a covered entity to provide meaning access to LEP individuals “eligible to be served or likely to be encountered.” HHS believes the adjustment to the language will provide greater clarity to covered entities seeking to abide by the requirement and empower covered entities to be cognizant of treating LEP individuals on a case-by-case basis to better serve their needs.

    The proposed rule also proposes to reinstate a requirement from the 2016 Final Rule that obligated covered entities to provide a notice of availability of language assistance services to better serve LEP individuals. The 2016 Final Rule had required these notices to be in “all significant publications,” which was declared to be burdensome and rescinded as part of the 2020 Final Rule. To that end, under the NPRM, the notice must be provided on an annual basis to participants, beneficiaries, enrollees and applicants, and upon request at any time. Additionally, the notice must be provided in a conspicuous manner on the covered entity’s health program or activity website (if one exists) as well as in other clear and prominent physical locations reasonably expected to be read or heard by individuals seeking services from the covered entities’ health programs or activities. By returning the requirement, HHS seeks to balance the importance of the notice with the burden on covered entities.

    HHS recognizes that LEP individuals and their families are at risk of not understanding a physician or other healthcare provider or any health protocols or treatments prescribed by those providers. Ensuring that LEP individuals understand all aspects of their health care and follow up helps reduce the risks of poor outcomes specific to this population, such as lower rates of outpatient follow up, poor medication, adherence, and difficulty understanding diagnosis and discharge instructions.

    Adherence to these requirements is particularly important in the telehealth context in light of the COVID-19 pandemic, and the proposed rule specifically addresses nondiscrimination in the delivery of telehealth services to LEP individuals.

    Revisions to Prohibition Against Disability Discrimination

    The 2016 Final Rule included definitions for a range of terms related to disability discrimination, including auxiliary aids and services; disability; qualified individual with a disability; and qualified interpreter for an individual with a disability. In the NPRM, HHS keeps the substantive definitions for these terms and adds a definition for “qualified reader” consistent with Title II of the American with Disabilities Act (ADA) to provide clarity to covered entities as well as protected individuals regarding the necessary qualifications of a reader, as required under the regulation.

    HHS also proposes to require covered entities to make reasonable modifications to policies, practices or procedures as necessary to avoid discrimination on the basis of disability, unless the covered entity can demonstrate that implementing the modifications would significantly change the nature of the health program or activity. HHS clarifies that the term “reasonable modifications” should be interpreted in a manner consistent with the term as set forth in the regulation implementing Title II of the Americans with Disabilities Act.

    Furthermore, as with the requirements specific to LEP individuals, the proposed rule specifically addresses nondiscrimination in the delivery of telehealth services to individuals with disabilities and requires a notice of the availability of auxiliary aids and services for individuals with disabilities.

    Revisions to Prohibition Against Sex Discrimination

    In a shift from the 2020 Rule, which declined to adopt a definition of “on the basis of sex,” HHS aligns regulatory requirements with federal court opinions to prohibit discrimination on the basis of sex, including sexual orientation and gender identity. Consistent with the US Supreme Court’s holdings in Bostock v. Clayton County, 140 S. Ct. 1731 (2020), the proposed rule codifies protections against discrimination on the basis of sex as including discrimination on the basis of sexual orientation and gender identity (see Federal Register Notice 86 Fed. Reg. 27984), stating that Section 1557 would be enforced consistent with Bostock.

    Additionally, the proposed rule includes other categories of sex discrimination, such as discrimination on the basis of sex characteristics, including intersex traits, and pregnancy or related conditions, including pregnancy termination. HHS proposes the inclusion of “sex characteristics” on grounds that discrimination based on anatomical or physiological sex characteristics is inherently sex-based.

    HHS also recognizes in the proposed rule that including “pregnancy or related conditions” is consistent with the longstanding interpretation of sex discrimination under Title IX, including HHS’s Title IX implementing regulation (45 CFR § 86.21(c)(2), (3); § 86.40(b)(1), (4), (5); § 86.51(b)(6); § 86.57(b)(d) (Title IX regulation)).

    Finally, HHS stated its belief that it could be beneficial to include a provision specifically prohibiting discrimination on the basis of pregnancy-related conditions as a form of sex-based discrimination. HHS is requesting comments on how it should do so and any impact that the Supreme Court decision in Dobbs v. Jackson Women’s Health Organization (see our previous client alerts, “Preparing for the demise of Roe v. Wade and the criminalization of abortion in some US states: Practical considerations for a post-Roe world” and “The overturning of Roe v. Wade”) has on the implementation of Section 1557 and how it should be reflected in the Final Rule.

    New Requirements for Operationalizing Compliance with Section 1557

    The proposed rule requires covered entities to develop and implement written policies and procedures to facilitate the implementation of Section 1557. HHS states that written policies and procedures will better equip covered entities to provide services in a nondiscriminatory manner, consistent with the goals of Section 1557.

    The proposed language requires covered entities, in their health programs and activities, to adopt and implement a nondiscrimination policy, grievance procedures (for covered entities employing 15 or more persons), language access procedures, auxiliary aids and services procedures, and procedures for reasonable modifications for individuals with disabilities.

    To help oversee the aforementioned policies and procedures, HHS proposes requiring covered entities with 15 or more employees to designate at least one employee to act as the entity’s Section 1557 coordinator. Persons in this role will be responsible for ensuring the covered entity’s compliance with the requirements under Section 1557 with regard to health programs and activities.

    Although this was similarly required under the 2016 Final Rule, HHS now expands on the obligation by acknowledging that some covered entities might prefer to spread out the responsibilities of a Section 1557 coordinator. In recognition of those covered entities, HHS proposes to permit covered entities to assign one or more designees to carry out the duties of a Section 1557 coordinator. These duties include: (1) receiving, reviewing and processing grievances filed under the grievance procedures; (2) coordinating the covered entity’s recordkeeping requirements; (3) coordinating effective implementation of the covered entity’s language access procedures; (4) coordinating effective implementation of the covered entity’s communication procedures; (5) coordinating the covered entity’s procedures for providing reasonable modifications for individuals with disabilities; and (6) coordinating training for employees.

    HHS also proposes to require the Section 1557 coordinator, along with other relevant employees, to undergo training on the covered entity’s written policies and procedures established pursuant to the rule. These trainings include instructing staff on the provision of language assistance services to LEP individuals and effective communication and reasonable modifications to policies and procedures for individuals with disabilities. HHS defines “relevant employees” in this context as those who “directly encounter or interact with individuals such as patients, clients, and members of the public.” Additionally, “employees are also considered relevant when they make decisions regarding the services individuals seek from a covered entity’s health programs and services.” The NPRM recognizes that many covered entities already have existing civil rights trainings for their employees and that those can be modified to comply with this proposed provision.

    Benefits Plan Design/Coverage

    When and how employee benefit group health plans may be subject to Section 1557 continues to evolve. Under the 2016 Final Rule, employer-sponsored group health plans were directly subject to Section 1557. Under the 2020 Final Rule, employer-sponsored group health plans that do not receive federal financial assistance and are not principally engaged in the business of providing healthcare were no longer considered covered entities subject to Section 1557. The expansive definition of covered entity in the NPRM, while similar in many ways to the 2016 Final Rule, does not explicitly include employee benefit group health plans as covered entities subject to Section 1557. In reaching this conclusion, HHS provides the following:

    “Although we still consider group health plans to be principally engaged in providing or administering health programs or activities […], many group health plans themselves are not recipients of federal financial assistance (as opposed to the employer or plan sponsor offering the group health plan or the third party administrator administering the group health plan), so inclusion of group health plans on the list may be confusing. That said, if [HHS] receives a complaint against a group health plan, we will evaluate the facts on a case-by-case basis to determine whether the group health plan is a covered entity subject to this part.”

    As a result, the NPRM would not directly apply to many employee benefit plans. However, HHS leaves the issue open, providing that it may determine on a case-by-case basis whether a group health plan might be treated as a covered entity subject to Section 1557 and requesting further comments on the topic. Further, the NPRM would apply to many benefit plan vendors, which would include, for example, insurers and third-party administrators. As a result, the NPRM will indirectly apply to virtually all employee benefit plans.

    Enforcement

    The NPRM proposes to add a provision affirming that enforcement of Section 1557 will be consistent with mechanisms provided under Title VI of the Civil Rights Act of 1964, Title IX of the Education Amendments of 1972, Section 504 of the Rehabilitation Act of 1973 and the Age Discrimination Act of 1975, and that private individuals may sue to enforce their rights under Section 1557. Through this lens, HHS clarifies that a covered entity can raise its belief that a provision of Section 1557, as applied to it, would violate federal conscience and religious freedom laws. Should a covered entity provide such a notification, HHS Office of Inspector General (OIG) will consider the facts and circumstances involved before determining whether to proceed with an investigation or enforcement activity or granting an exemption or modification to that covered entity. The NPRM further clarifies that an exemption or modification for one circumstance does not necessarily extend that exemption or modification for other circumstances. Previously, neither the 2016 Final Rule nor the 2020 Final Rule addressed the applicability of federal conscience or religious freedom laws to Section 1557 enforcement.

    Amendments to the Nondiscrimination Regulatory Provisions in Other CMS Programs

    The 2020 Rule amended CMS regulations governing the Medicaid, CHIP and PACE programs, as well as issuers offering coverage to group and individual markets and exchange-related programs, to ensure greater consistency in civil rights enforcement across HHS’s different programs. The proposed rule amends these regulations to include discrimination on the basis of sexual orientation and gender identity as prohibited forms of discrimination based on sex. HHS believes these proposals would promote consistency across all programs of policies and requirements prohibiting discrimination on the basis of sexual orientation or gender identity.

    Conclusion

    HHS believes that its proposed rule will reinstate protections from discrimination on the basis of race, color, national origin, sex, age or disability in covered health programs and activities in a manner consistent with the statutory text of Section 1557 and congressional intent and in line with the 2016 Final Rule. To broadly achieve these goals, the proposed rule also requires covered entities to provide a notice of nondiscrimination, relating to their health programs and activities, to participants, beneficiaries, enrollees and applicants of its health programs and activities, and members of the public.

    Given the copious detail that HHS put into the NPRM, including citations to peer-reviewed articles, case law, federal guidance documents and other materials, we anticipate that the NPRM will be finalized in materially the same format as proposed. However, we will monitor comments closely and will report any material developments. Public comments on the NPRM are due on or around October 4, 2022, or 60 days after publication of the NPRM in the Federal Register.

    Authors

    Jacob M. Mattinson

    Partner

    Chicago

    Todd A. Solomon

    Partner

    Chicago

    More insights

  • How Does the FMLA Apply to a Remote Workforce?

    How Does the FMLA Apply to a Remote Workforce?

    ARTICLE / CLIENT ALERT

    How Does the FMLA Apply to a Remote Workforce?

    August 4, 2022

    Read time: 9 min

    Key takeaways
    Overview

    The Family and Medical Leave Act (FMLA) was enacted in 1993, a year when the idea of working a corporate job from a living room was rare. When the law was passed, the FMLA didn’t contemplate a remote workforce. Now, and especially post-pandemic, many companies are embracing a fully remote workforce (e.g., sales representatives, healthcare medical device technicians and software engineers). While employees’ needs for a leave of absence have always been around, remote employment and its effects on the applicability of the FMLA requirements has not. For well over two years, many employees have been working from home. Some report to a manager at the headquarters or worksite. Plenty of remote employees, however, report to an individual who also works remotely. The new remote landscape is making what used to be an easy application of FMLA eligibility into a difficult analysis. This article examines the FMLA regulatory framework for remote employees, a recent Texas federal court decision on the issue and the practical options that employers have moving forward.

    In depth

    THE FMLA REMOTE EMPLOYEE FRAMEWORK

    The FMLA requires that certain private employers provide eligible employees with up to 12 weeks of unpaid leave from work to take care of their serious health condition or a family member’s serious health condition. A private employer with more than 50 employees within a 75-mile radius of the employee’s worksite must provide the requisite 12-week leave. An eligible employee is one who meets all of the following conditions:

    • Is employed for at least 12 months
    • Has been employed for at least 1,250 hours during the 12-month period immediately preceding the start of the leave
    • Is employed at a worksite where 50 or more employees are employed by the employer within 75 miles of that worksite.

    One of the most challenging aspects of determining eligibility for leave under the FMLA is whether the employee is employed at a “covered employer” (i.e., a worksite with 50 or more employees within a 75-mile radius).

    The FMLA is silent on its applicability to remote workers. However, the US Department of Labor’s implementing regulations state that “[f]or employees with no fixed worksite, . . . the worksite is the site to which they are assigned as their home base, from which their work is assigned, or to which they report.” Further, “[a]n employee’s personal residence is not a worksite in the case of employees . . . who travel a sales territory and who generally leave to work and return from work to their personal residence, or employees who work at home, as under the concept of flexiplace or telecommuting.”

    A CASE STUDY ON FMLA’S APPLICABILITY TO REMOTE EMPLOYEES

    Recently, a Texas court analyzed the remote employee question and the applicability of the FMLA. In Landgrave v. Fortec Medical Inc., a remote employee sued her former employer, Fortec, alleging that it failed to provide her leave under the FMLA after concluding that she was not eligible because the company did not have 50 employees within a 75-mile radius in Texas. Landgrave was employed as a surgical laser technician and was hired as a remote employee. Landgrave argued her “worksite” under the FMLA was the company’s headquarters in Ohio, which did have more than 50 employees. Fortec argued that her “worksite” was in Texas.

    Although Landgrave was hired through Fortec’s Ohio headquarters, she lived and primarily worked in Texas (sometimes her work required her to travel to other states, but not Ohio). Landgrave’s supervisor also was a remote employee working from Texas. The supervisor managed the south-central region of Texas, oversaw logistics for the region, paired surgical technicians with assignments, monitored Landgrave’s performance and handled Landgrave’s requests for time off.

    The court denied Fortec’s motion for summary judgment because it found that there was a genuine issue of fact as to Landgrave’s worksite and therefore her FMLA eligibility. To have won summary judgment, Fortec would have had to establish that the Ohio headquarters worksite was not her home base, the site that assigned her work or the site to which she reported. A brief overview of each issue is below.

    • Home Base. The court found that there were insufficient facts to establish that the Ohio location was Landgrave’s home base. Using the Worker Adjustment and Retraining Notification Act as a guide, the court stated that an employee’s home base “must at a minimum be a location at which the employee is physically present at some point during a typical business trip” and “refers not to the physical base of the employer’s operations . . . but rather to the physical base of the employee.” Since Landgrave was never physically present in Ohio, she could not establish Ohio as her home base.
    • Assignment of Work. The court found that there was a genuine issue of fact regarding where the assignments were created/originated, and the dispute on this element precluded summary judgment. The assigning site is the “source of the day-to-day instructions” given to the employee. It is not determined by the location of payroll or other centralized managerial or personnel functions. It is not merely from where the instructions are passed, but rather “where the people were who were ultimately responsible for creating and receiving the assignment information.” In Landgrave, the employee’s supervisor assigned work from his home in Texas, and he directed cases to specific employees within the Texas region. However, Landgrave characterized her supervisor’s assignment of work as “click[ing] the mouse on his computer at his house and send[ing] the[] instructions from [Ohio] to one technician or the other in his region.” The court found that while Landgrave’s supervisor appeared to have more of a role than a “mere conduit,” his duties did appear ancillary to the actual assignment activity, which created a triable issue of fact for the jury as to whether that assignment came from headquarters in Ohio.
    • Reporting Worksite. The court also found there was a genuine issue of fact as to Landgrave’s supervisor’s reporting structure and authority, such that the issue also precluded summary judgment. The location to which an employee reports is determined based on the “location of the personnel who were primarily responsible for reviewing . . . reports and other information sent by the [employee], in order to record [tasks], assess employee performance, develop new sales strategies, and the like.” It was undisputed that Landgrave’s supervisor did not review reports from her. In fact, Landgrave sent reports only to Ohio and never sent anything to her supervisor. Fortec focused on the fact that her Texas supervisor assessed her employment and was empowered to discipline and evaluate her. However, the company’s claim lacked factual support at the summary judgment stage, as there was no evidence that her supervisor did any evaluations or had the power to impact her employment status. For those reasons, Fortec’s argument on this element was not strong enough to support summary judgment.

    Since the court’s ruling, the parties reached a confidential settlement concerning Landgrave’s FMLA claims.

    PRACTICAL OPTIONS FOR EMPLOYERS WITH A REMOTE WORKFORCE

    Given the FMLA legal framework described above and the insight from the Landgrave decision, employers have three options to manage FMLA leave with a remote workforce.

    1. Conservative Approach. Employers can take the most conservative approach by determining that the FMLA applies to remote employees (assuming the length of employment and hours worked conditions are met). Approaching eligibility from this perspective will help employers avoid potential violations of the FMLA and related legal claims. However, in some factual situations, this option may provide more generous leave than the employees are entitled to receive, and FMLA leave is often difficult for employers to manage.
    2. Affirmative Approach. Employers can undertake the FMLA analysis themselves by affirmatively assigning either a reporting site or an assignment site, and then ensuring that such worksite meets the requirement of 50 or more employees within 75 miles. This approach appears to be supported by the FMLA regulations, which state, “[f]or employees with no fixed worksite . . . the worksite is the site to which they are assigned as their home base, from which their work is assigned, or to which they report.” Employers should note that the day-to-day facts may undermine an employer’s express designation, however. For example, if an employer by policy and written agreement determines that all remote employees report to X location, but no employees ever actually report to X location, those facts may undermine the employer’s designation of the reporting site. The same concept applies to an assignment site. If an employee never receives assignments, or receives only a small number of assignments, from Y worksite, a court may have trouble concluding that Y is indeed the accurate worksite on which to base the 75-mile radius test. Either way, as seen in Landgrave, courts have the discretion to use any of the three worksite bases outlined above for the 75-mile test.
    3. The Landgrave Approach. Employers can take a more liberal approach and analyze the FMLA application to the remote workforce on a case-by-case basis. This would involve examining each employee’s home base, assigning site and reporting site, then determining whether any of those locations have 50 or more employees within a 75-mile radius. If they do not, the employee would not be eligible for FMLA leave. But as shown in Landgrave, this approach has a higher risk of litigation due to potential factual disputes about the sites at issue.

    In the wake of COVID-19, more businesses are permitting their employees to work remotely. When it comes to family and medical leave (paid or unpaid), employers should make sure they understand the eligibility rules for their remote employees under federal and (sometimes conflicting) state law. In the case of the FMLA, it is important for employers to understand the workflow of the business and to track the various worksites for all employees, including the remote ones.

    Authors

    Brian Mead

    Partner

    Chicago

    More insights

  • Carbon Capture, Utilization and Sequestration Tax Benefits under the Proposed Inflation Reduction Act

    Carbon Capture, Utilization and Sequestration Tax Benefits under the Proposed Inflation Reduction Act

    ARTICLE / CLIENT ALERT

    Carbon Capture, Utilization and Sequestration Tax Benefits under the Proposed Inflation Reduction Act

    August 4, 2022

    Read time: 7 min

    Key takeaways
    Overview

    On July 27, 2022, Senate Majority Leader Chuck Schumer (D-NY) and Senator and Energy and Natural Resources Chair Joe Manchin (D-WV) announced an agreement on a proposed reconciliation package called the Inflation Reduction Act of 2022, HR 5376, 117th Cong. (Act). The included tax credits and benefits related to Carbon Capture, Utilization and Storage (CCUS) projects represent some of the most notable and impactful aspects of the proposed Act. They include (1) an increase in tax credit value to $85 per ton; (2) an added tax credit value for direct air capture (DAC); (3) a decrease in the size (emissions eligibility thresholds) of qualifying projects and (4) a 45Q tax credit through direct pay.

    In depth

    The Act also contains a variety of beneficial modifications to existing tax credits aimed at propping up the developing CCUS industry and appears to be responsive to industry and policy suggestions that will allow for meaningful development of CCUS projects, broaden the number of CCUS-related projects that can benefit from these tax credits and potentially increase the number and character of CCUS industry participants.

    CCUS is the process of injecting carbon oxides into underground geological formations for permanent storage to be trapped or transformed as opposed to being emitted into the atmosphere. CCUS has gained momentum in recent years as a manner by which carbon emissions may be limited in an effort to combat climate change. The US government has supported this effort by providing certain tax credits to owners and developers of CCUS projects, often referred to as “45Q” tax credits in reference to the Internal Revenue Code section that provides for these credits.

    45Q tax credits are currently based on the amount of carbon oxides captured and sequestered, calculated by the metric ton. For projects with carbon capture equipment placed in service on or after February 9, 2018, these tax credits will accrue to the person or entity who owns the capture equipment and physically or contractually provides for the disposal or utilization of the carbon oxides. (The value of the existing 45Q tax credit is about $50 per ton of stored carbon oxide.)

    A DEEPER DIVE

    The Act contains several important broadening changes to the 45Q tax credit, all of which are intended to help spur CCUS project and technological development, with the ultimate goal of facilitating a self-sustaining, market-driven CCUS industry.

    • Increase in Tax Credit Value to $85 per Ton. The Act increases the value of the 45Q tax credit for carbon oxide geological sequestration to $85 per ton (up from the current $50 per ton). Clean air policy advocates have argued that $85 per ton is a threshold tax credit value to incentivize hard-to-abate industrial businesses, such as petrochemicals, cement, steel and refineries, to incorporate CCUS into their facilities and receive ample benefit from the tax credit to justify the necessary capital outlay to develop CCUS facilities. The Act also extends the tax credit so that it is available for projects beginning construction before 2033.
    • Added Tax Credit Value for Direct Air Capture. The CCUS industry also includes emerging technologies to capture CO2 that is already present in the atmosphere. The Act contains a special rule for DAC facilities under which the 45Q tax credit is valued at approximately $180 per ton, as opposed to the $85 per ton for carbon oxide geological sequestration. Because most DAC technologies in today’s market are early stage or experimental in nature, the additional increase in 45Q tax credits for DAC facilities is aimed at creating synthetic economics for these projects to allow them to receive additional capital to help develop DAC technologies at scale and eventually make DAC businesses widespread and profitable.
    • Decrease the Size (Emissions Eligibility Thresholds) of Qualifying Projects. Under the current 45Q tax credit regime, only some of the United States’ largest carbon emitting projects qualify for 45Q eligibility: Power plants must emit more than 500,000 tons per year; industrial facilities must emit more than 100,000 tons per year; and DAC facilities must capture at least 100,000 tons per year. The Act modifies the definition of “Qualified Facility” to lower these thresholds to 18,750 for power plants; 12,500 for industrial facilities and 1,000 tons of carbon oxide captured per year for DAC facilities. These lower thresholds will significantly broaden the universe of projects that can economically benefit from 45Q tax credits, potentially expanding the adoption of CCUS and enhancing its prevalence. Notably, these lower thresholds will likely allow for many fossil fuel-based energy generation facilities to be eligible for 45Q tax credits by implementing CCUS.
    • 45Q Tax Credit through Direct Pay. Direct pay, or the ability of the applicable taxpayer to claim the value of the 45Q tax credit through a tax refund as if it were an overpayment of taxes, has long been prophesied as the fundamental missing piece required for CCUS to garner sufficient investment capital to throttle project development forward to significant scale. The logic being that by receiving the 45Q tax benefits in the form of direct pay, project developers and sponsors will avoid the overly burdensome (and often costly) process of raising tax equity to utilize the traditional tax credits generated through 45Q. Direct pay will, theoretically, allow for project developers and sponsors to reap more of the benefits of the 45Q tax credit instead of having to share or transfer those benefits to financial institutions with significant tax appetites. Under the Act, the 45Q tax credit would also be eligible, in the alternative, for transfer to unrelated persons in a non-taxable cash sale, which is another route that could simplify and reduce the costs associated with developing CCUS.

    Reading these proposed revisions together, it is clear that one of the goals of the Act is for the US government to spur the growth of CCUS by encouraging additional investment and wider application and adoption. Even if the dollar values and threshold numbers in the Act are not spot on from an industry perspective, they should allow for clearer modeling of CCUS project development budgets and returns and, with direct pay and tax credit transferability, increased liquidity options. At a time when investment dollars are eager to participate in renewable energy and energy transition businesses, these revisions to the 45Q tax credit are likely to help the CCUS industry attract significant capital investment.

    The Act remains under review by the US Senate’s chamber parliamentarian, but a vote by the Senate is expected in August 2022. Any tax credits included in the Act will take time to go into effect, and the trickle-down impacts will take even more time, however, an approved and enforceable version of the Act will provide much-needed clarity for project developers, investors and lenders active in the renewable energy and energy transition space and foster further investment in CCUS.

    McDermott’s CCUS team and Tax Practice Group are working on several leading CCUS transactions and policy considerations. Please don’t hesitate to reach out to your regular McDermott lawyer or the authors of this article with any related questions or if you would like to discuss potential CCUS transactions or general market activity.

    Authors

    Heather Cooper

    Partner

    Miami

    Carl J. Fleming

    Partner

    Washington, DC

    More insights

  • The Tale of Two CE Programs: OIG Compares Healthcare Provider and Third-Party Continuing Education in Recent Advisory Opinion

    The Tale of Two CE Programs: OIG Compares Healthcare Provider and Third-Party Continuing Education in Recent Advisory Opinion

    ARTICLE / CLIENT ALERT

    The Tale of Two CE Programs: OIG Compares Healthcare Provider and Third-Party Continuing Education in Recent Advisory Opinion

    August 3, 2022

    Read time: 12 min

    Key takeaways
    Overview

    The Office of Inspector General of the US Department of Health and Human Services (OIG) issued Advisory Opinion 22-14 (AO 22-14) on June 29, 2022, concerning continuing education (CE) programs to be offered by an ophthalmology practice. The requestor posed four different fee models to OIG, of which OIG only approved one: when the practice charges a fair market value (FMV) fee to the attendees. The other three models involved the practice of either providing the CE program for free or accepting industry sponsorship funding, such as from pharmaceutical and medical device manufacturers.

    As discussed below, the apparent distinguishing fact of these proposed arrangements from the more “traditional” CE support of third-party CE programs provided by pharmaceutical and medical device companies was that the CE program was offered by a referral recipient rather than an independent third-party CE organizer. Whether provider-run or third-party-run, this opinion may be useful to healthcare providers and manufacturers in evaluating their respective CE provision and sponsorship activities.

     

    In depth

    The AO 22-14 requestor is an ophthalmology practice that receives about half of its surgical referrals from optometrists outside of the practice. Post-surgery, the requester and the ophthalmologists co-manage the patients. The requestor proposed to offer two accredited CE programs annually for optometrists on new technologies and pharmacological protocols in the treatment of patients undergoing ophthalmic surgery. The CE would be taught by experienced instructors, both practice physicians and independent physicians. External faculty would be paid an honorarium plus expenses at an FMV rate that would not take into account the volume or value of past business generated or potential future business generated for the requestor or for an industry sponsor by the faculty.

    The CE programs offered under the proposed arrangements would be open to all local optometrists in the requestor’s service area, which comprises an approximately 20-mile radial area. The course options would consist of a full-day CE program providing six hours of CE credit and an evening CE program providing two hours of CE credit. Attendance would not be limited to optometrists who refer to the requestor, and there would be no requirement that attendees refer patients to the requestor as a condition of attendance. The selection of attendees also would not be based on past or expected prescribing or ordering of any industry sponsor’s items or services payable by federal healthcare programs. The requestor estimated that 100 optometrists would attend the full-day program and 30 to 50 optometrists would attend the evening program.

    PROPOSED ARRANGEMENTS

    The requestor proposed offering the CE program with four variations (the proposed arrangements):

    • Proposed Arrangement A: The requestor would charge attendees FMV registration fees to attend the CE programs.
    • Proposed Arrangement B: The requestor would not charge any registration fee and the requestor would cover all costs of the CE program.
    • Proposed Arrangement C: The requestor would not charge any registration fee and would seek pharmaceutical and medical device sponsors to offset some or all of the CE program costs. The requestor would fund any shortfall or donate any sponsorship funds that exceeded the program costs to a local charity.
    • Proposed Arrangement D: The requestor would charge a registration fee and offset some of the cost of the CE program with pharmaceutical and medical device manufacturer sponsorships. The requestor would fund any shortfall or donate any sponsorship funds that exceeded the program costs to a local charity.

    OIG ANALYSIS

    Under these facts, OIG concluded that each of the proposed arrangements would implicate the federal Anti-Kickback Statute (AKS) because, under each proposal, the requestor would give something of value to local optometrists who are actual or potential referral sources of federal healthcare program beneficiaries. Additionally, under proposed arrangements C and D, the requestor, external faculty members and attendees would receive remuneration from industry sponsors who may, in turn, receive orders for their products from the requestor, external faculty members and attendees.

    Interestingly, OIG spent a fair amount of time discussing its 2020 Special Fraud Alert on Speaker Programs (SFA) which highlights the risks associated with speaker programs directly organized and paid for by pharmaceutical and medical device companies for healthcare professionals (HCPs). Although recognizing the differences between speaker programs and the proposed arrangements, OIG stated that the following suspect characteristics identified in the SFA may be instructive for those involved in CE events:

    SFA Suspect Characteristics The Requestor’s CE Programs
    A company sponsors a speaker program where little or no substantive information is actually presented.
    • CE program content would address new technology and pharmacological practice treatment protocols relevant to treating patients who require ophthalmic surgeries, including the requestor’s patients.
    • Faculty, which would include the requestor’s physicians, would possess first-hand professional experience that enables them to provide expertise and input on the CE program topics.
    • The CE programs would be approved for CE credit by an appropriate professional CE certification board.
    Alcohol is available or a meal exceeding modest value is provided to attendees.
    • Only modest food items, such as bagels, coffee, pizza, and non-alcoholic refreshments, would be provided.
    The program is held at a location not conducive to the exchange of educational information.
    • The venue would be one of the requestor’s offices or another appropriately sized conference space conducive to educational presentations in a geographic location convenient to the requestor’s service area.
    Selection of HCP speakers or attendees is based on past or expected revenue that these individuals have generated or will generate by prescribing or ordering the company’s products.
    • The CE programs would be open to all local optometrists. Attendance would not be limited to optometrists who refer to the requestor, and there would be no requirement that attendees refer patients to the requestor as a condition of attendance.
    • Neither the selection of attendees nor the selection of external faculty would be based on referrals to the requestor or past or expected prescribing or ordering of any industry sponsor’s items or services payable by federal healthcare programs.
    A company pays HCP speakers more than FMV for the speaking service or pays compensation that takes into account the volume or value of past business generated or potential future business generated by the HCPs.
    • External faculty would be paid an honorarium plus expenses at an FMV rate that would not take into account the volume or value of past business generated or potential future business generated for the requestor or for an industry sponsor by the faculty presenter.

    Although OIG stated that, generally, none of the proposed arrangements exhibit the types of suspect characteristics highlighted in the SFA, OIG only concluded that one proposed arrangement (Proposed Arrangement A) would pose a sufficiently low risk of fraud and abuse under the AKS, while proposed arrangements B, C and D would present more than a minimal risk.

    • Proposed Arrangement A: Here, the requestor would charge attendees a registration fee consistent with FMV for such CE programs. To the extent revenue generated from the FMV registration fees does not cover the CE programs’ expenses, the requestor would cover those costs. Conversely, to the extent the revenue from the registration fees exceeds the CE programs’ expenses, the requestor would donate the excess amount to a local charity. The requestor certified that the registration amounts it proposes to charge and the anticipated number of attendees comport with the estimated amount of expenses, such that any revenue shortfall or overage should not be substantial. In this scenario, and in combination with the low-risk aspects of the program discussed below, OIG concluded this proposed arrangement presented sufficiently low risk.
    • Proposed Arrangement B: OIG stated that because this arrangement would involve the provision of free goods or services to an existing or potential referral source that have independent value to the recipient, there is heightened risk this remuneration could induce the optometrist attendees and external faculty to refer surgical patients, including federal healthcare program beneficiaries, to the requestor, which could result in inappropriate patient steering.
    • Proposed Arrangement C: OIG stated that because this arrangement would involve the provision of free goods or services to an existing or potential referral source that have independent value to the recipient, there is heightened risk this remuneration could induce the requestor, external faculty and the optometrist attendees to prescribe or order a sponsoring company’s products, including those payable by federal healthcare programs, which could result in inappropriate patient steering or inappropriately increased costs to federal healthcare programs.
    • Proposed Arrangement D: OIG highlighted the fact that the requestor is an ophthalmology practice and potentially a direct referral source for sponsoring medical device and pharmaceutical companies, in contrast with more traditional CE program organizers that often are independent entities not directly involved in the provision of patient care (e.g., a professional organization). By paying sponsorships to the requestor to fund its CE programs, the medical device manufacturers and drug companies would pay expenses that the requestor otherwise would incur. Accordingly, OIG could not conclude that the industry sponsorships in Proposed Arrangement D would pose a sufficiently low risk of fraud and abuse to issue a favorable opinion.

    ANALYSIS AND TAKEAWAYS

    For providers: OIG’s position is relatively clear: providers who are referral recipients of attendees should charge an FMV fee for attending an accredited CE program. This position is consistent with other OIG guidance expressing concerns about a free or below-FMV offering that has substantial independent value to a referral source. OIG also appears to view industry sponsorships of provider-run CE with skepticism. The sponsorship dollars can act to subsidize the attendee tuition cost, which conveys remunerative benefit to the attendees, or reduce the hosting provider’s costs or otherwise provide additional revenue, which conveys a remunerative benefit to the hosting provider.

    The nuanced question for providers is distinguishing accredited CE from other types of educational offerings that a healthcare provider may offer. Many healthcare providers offer educational classes to their communities, often as part of their public health or non-profit missions. Some, though not all, of these classes provide CE or other credits. In addition, many healthcare institutions host conferences and solicit industry and vendor sponsorship. As is often the case with interpreting unfavorable advisory opinions, one has to keep in mind the very high bar OIG applies; the arrangement must pose no more than minimal risk to obtain a favorable opinion. Although it is the best of times to sit within a favorable opinion, it is not necessarily the worst of times for an activity to fall outside of a favorable opinion. Doing so, however, means that the arrangement merits a careful evaluation of the facts and circumstances to assess risk level. In light of AO 22-14, providers may wish to consider evaluating their educational programming activities and policies.

    For manufacturers: OIG’s position on industry-sponsored CE provided by a third party is somewhat less clear. Industry can take comfort in OIG’s acknowledgment that “CE programs often are fully or partially subsidized by commercial sponsors that provide educational grants or other funding to CE program organizers” who “often are independent entities not directly involved in the provision of patient care […].” However, OIG also says “there is heightened risk that [industry sponsorships] could induce [the requestor], external faculty and attendees to prescribe or order a sponsoring company’s products, including those payable by federal healthcare programs, which could result in inappropriate patient steering or inappropriately increased costs to federal healthcare programs.” Although this statement was made in the context of a provider-run CE program, it carries a risk of being taken out of that context and applied to third-party CE programs and interpreted that OIG considered these activities as posing more risk than they actually do.

    The industry has long relied on the PhRMA Code on Interactions with Health Care Professionals and the AdvaMed Code of Ethics (collectively the codes), which allow pharmaceutical and medical device companies to provide financial support to third-party conference sponsors to reduce the overall conference registration fee for all attendees, so long as the sponsor retains control over the selection of content, faculty, educational methods, materials, and venue or digital platform in accordance with the conference guidelines. The codes do not expressly address the circumstance where the third-party conference organizer has physician ownership or is a physician practice. It may be that PhRMA and AdvaMed assumed that third-party conference hosts did not have physician ownership, such as professional societies.

    The codes also provide guidance on the nature of the conference, such as that the conference or meeting should be held at an appropriate location where (a) the gathering is primarily dedicated, in both time and effort, to promoting objective scientific and educational activities and discourse (one or more educational presentation(s) should be the highlight of the gathering), and (b) the main incentive for bringing attendees together is to further their knowledge on the topic(s) being presented. Finally, the codes state that financial support should not be offered for the costs of travel, lodging or other personal expenses of non-faculty healthcare professionals attending third-party scientific or educational conferences or professional meetings, either directly to the individuals attending the conference or indirectly to the conference’s organizer. Similarly, funding should not be offered to compensate for the time spent by healthcare professionals attending the conference or meeting.

    Although these codes are voluntary and do not rise to the level of OIG guidance, OIG has previously encouraged compliance with the codes. It seems likely that organizing CE within the guidance of the codes would still result in a low-risk conclusion when the support is to a third-party CE program, since the distinguishing factor in AO 22-14 was that the requestor was not a third-party CE organizer. CE support aligned with the relevant code, but made to a provider organizing the CE program, would require additional analysis in light of AO 22-14 to assess the level of potential risk.

    Another point of potential confusion in AO 22-14 is whether there is a difference between “free CE” from “below-FMV CE” in the third-party-organized programs with industry sponsorship. AO 22-14 does not discuss differences, probably because the difference did not change OIG’s conclusion that either presents more than minimal risk under the AKS when the CE is offered by a potential referral source. Although the guidance under the codes tend to focus on third-party sponsorships that reduce CE tuition cost rather than eliminate it, a third party not charging tuition similarly could also be low risk where the program otherwise complies with the relevant code and with the SFA.

    Despite these questions, AO 22-14 is a useful reminder that industry CE sponsorships or grants to third-party CE organizers should be evaluated for AKS compliance.

    Authors

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    James A. Cannatti III

    Partner

    Washington, DC

    More insights

  • EU Foreign Subsidies Regulation to Impact EU and Cross-Border M&A Antitrust Review Starting in 2023

    EU Foreign Subsidies Regulation to Impact EU and Cross-Border M&A Antitrust Review Starting in 2023

    ARTICLE / CLIENT ALERT

    EU Foreign Subsidies Regulation to Impact EU and Cross-Border M&A Antitrust Review Starting in 2023

    August 2, 2022

    Read time: 14 min

    Key takeaways
    Overview

    On June 30, 2022, the Council of the European Union (Council) and the European Parliament (Parliament) reached a political agreement on the Regulation on foreign subsidies distorting the internal market (FSR or Regulation).

    The FSR aims to redress the perceived regulatory gaps left by current EU competition law and trade defence rules which, at present, risk subsidies granted by third countries (foreign subsidies) distorting the EU internal market and undermining the level playing field level between companies active in the European Union that receive subsidies from EU member states, and those that receive subsidies from third countries.

    The Regulation is expected to enter into force by the end of this year, which would mean it will be applicable by mid-2023 (i.e. six months after entry into force) save for certain exceptions such as the prior notification obligations in relation to M&A and public procurement. These obligations will only start applying nine months after entry into force, thus more towards Q3 – Q4 of 2023.

    In summary, the Regulation ushers in (i) obligations to notify the European Commission (Commission) on M&A deals and public procurement offers which meet certain criteria, suspending implementation of the M&A deal or the award of the contract respectively, and (ii) a market investigation tool for the Commission. In addition, the Regulation also provides the Commission with extensive investigatory and punitive fiscal powers.

    It is important to note that the FSR supplements existing EU competition rules (including those regulating merger control and State aid) and foreign direct investment rules in the various EU Member States. The Regulation is therefore expected to have a significant impact on M&A deals and public tender offers that benefit from subsidies granted by non-EU countries, as additional obligations and limitations (on top of the already applicable EU rules) may apply.

    The Regulation increases regulatory scrutiny for companies that benefit from foreign subsidies and are looking to do business in the European Union. These companies will need to carefully assess the rules as they may be met with these additional obligations when doing business in the European Union

    In depth

    Background

    In June 2020, the Commission adopted a White paper on levelling the playing field as regards foreign subsidies (White Paper), which kicked off a public debate on the topic of distortive foreign subsidies.

    In its White Paper, the Commission stated that “[i]n today’s intertwined global economy, foreign subsidies can […] distort the EU internal market and undermine the level playing field.” In particular, the Commission referred to the fact that foreign subsidies appear to have increasingly facilitated the acquisition of EU undertakings, influenced investment decisions and have distorted the market behaviour of their beneficiaries. The Commission went on to explain that within the European Union, the Single Market and its rule book ensure a level playing field for all Member States and economic operators through well-enforced competition rules.

    Notably, EU State aid rules (which form part of the European Union’s competition rules) ensure that subsidies by Member States are compatible with the internal market. The concept of State aid in the European Union refers to an advantage in any form whatsoever (e.g. direct grant, loan, guarantee, etc.) conferred by Member States to undertakings on a selective basis. In principle, and except for limited circumstances, State aid is prohibited in the European Union.

    As EU State aid rules only apply to public support granted by EU Member States, whilst subsidies granted by non-EU authorities fall outside EU State aid control, the Commission considered that there is a risk that such subsidies would distort competition in the European Union’s internal market and result in an uneven playing field between European and non-European companies active in the market.

    Apart from the general concerns about foreign subsidies provided to undertakings in the European Union, the Commission also highlighted in its White Paper the specific concerns about foreign subsidies in an M&A context. It explained, inter alia, that foreign subsidies may lead to excessive purchase prices (outbidding) as the subsidised acquirer is able to pay a higher price to acquire the asset than it would otherwise have paid, thus possibly distorting the valuation of EU assets, and at the same time preventing non-subsidised acquirers from achieving efficiency gains or accessing key technologies.

    The Commission also highlighted the impact of foreign subsidies on public procurement, explaining that although the EU procurement markets are largely open to third country bidders, EU companies do not always compete on an equal footing with companies benefiting from foreign subsidies. Subsidised companies may be able to make more advantageous offers, thus either discouraging non-subsidised companies from participating in the first place, or winning contracts to the detriment of non-subsidised, yet more efficient, companies.

    The Commission therefore sought to close the above-summarized regulatory gaps highlighted in its White Paper by proposing a new legislative tool to ensure a level playing field between European and non-European companies active in the European Union.

    The Regulation

    Under the FSR, the Commission will have the power to investigate non-EU financial contributions which benefit companies engaging in economic activity in the European Union in order to redress any distortive effects. The Regulation includes rules relating to State aid, merger control, public procurement and trade. Specifically, the Regulation provides three tools aimed at redressing distortive effects of foreign subsidies, each of which are outlined below.

    (i) Who does the Regulation Target?

    The Regulation is essentially aimed at undertakings (including public undertakings (in)directly controlled by the state) that engage in an economic activity in the European Union’s internal market and that receive(d) a foreign subsidy. In turn, a foreign subsidy is defined in the Regulation as (i) a direct or indirect financial contribution by a third country (i.e. non-EU), which (ii) confers a benefit to an undertaking engaging in an economic activity in the internal market and which (iii) is limited, in law or in fact, to one or more undertakings or industries. This definition of “foreign subsidy” is broadly in line with the definition of “State aid”, applicable to EU Member States.

    As per the Regulation, “financial contributions” include, inter alia, (i) the transfer of funds or liabilities (e.g. capital injections, grants, loans, loan guarantees, debt forgiveness, fiscal incentives, etc.), (ii) the foregoing of revenue otherwise due (e.g. tax exemptions), and (iii) the provision or purchase of goods or services.

    In addition, the Regulation sets out categories of foreign subsidies that are considered either “most likely” or “unlikely” to distort the internal market:

    • A foreign subsidy is “unlikely” to distort the internal market if its total amount does not exceed EUR 4 million over any consecutive period of three financial years.
    • Examples of foreign subsidies “most likely” to distort the internal market are those granted to ailing undertakings, those granted in the form of unlimited guarantees, foreign subsidies enabling an undertaking to submit an unduly advantageous tender, foreign subsidies directly facilitating a transaction, or an export financing measure that is not in line with the OECD Arrangement on officially supported export credits.

    (ii) The Commission’s Powers under the Regulation in a Nutshell

    The Commission will enjoy broad powers under the Regulation. It will have the power to:

    • Investigate and request information (including from third countries)
    • Interview natural or legal persons (insofar as consent is provided)
    • Carry out inspections (within and outside the European Union although the latter requires consent from the government concerned)
    • Impose interim measures (but not when public procurement procedures are concerned)
    • Launch market investigations
    • Approve or block deals
    • Accept commitments or impose redressive measures (such as reducing capacity/market presence, divestments, repayments of foreign subsidies, ordering the dissolution of a transaction, the licensing on FRAND-terms, requiring the undertaking to adapt its governance structure, ordering the publication of R&D results, ordering the companies to refrain from making certain investments, etc.)
    • Impose fines.

    In terms of its power to impose fines, the Commission will be able to impose:

    • Fines of up to 1% of the aggregate turnover of the undertaking or association of undertakings concerned in the preceding financial year for providing incorrect, incomplete or misleading information in response to an information request or in a notification of a transaction, or for not supplying the information within the prescribed time limit, refusing to submit to inspections, providing incorrect or misleading answers in interviews, failing to provide required books or other records during inspections or failure to comply with the conditions for access to the file or the terms of disclosure imposed by the Commission.
    • Fines of up to 10% of the aggregate turnover of the undertaking concerned in the preceding financial year for non-compliance with a Commission decision imposing commitments, interim or redressive measures, or for certain infringements relating to notifications of transactions or public procurement procedures (as described in further detail below).
    • Periodic penalty payments of up to 5% of the average daily aggregate turnover of the undertaking or association of undertakings concerned in the preceding financial year for each working day of delay or non-compliance for the cases mentioned in the first two bullet points above.

    Notifications of M&A Deals

    The FSR provides for a “notification-based” tool for the Commission with which it will be able to investigate (and thus approve or block) “notifiable transactions”, i.e. those involving a financial contribution by a non-EU government, and where:

    • The target (in the case of acquisitions), at least one of the merging parties (in the case of mergers) or the JV (in the case of a joint venture) is established in the European Union and generates an EU turnover of at least EUR 500 million, and
    • All undertakings involved in the transaction were granted combined aggregate financial contributions in the three financial years prior to notification of more than EUR 50 million from third countries.

    Apart from these “notifiable concentrations”, the Commission may also request prior notification of any transaction at any time prior to its implementation where the Commission suspects that foreign subsidies may have been granted to the undertakings concerned in the three years prior to the transaction – in which case, that concentration is deemed a “notifiable concentration”.

    Much as in EU merger control, M&A deals that meet these criteria will need to approved by the Commission before they can be closed (known as the standstill obligation). In another similarity with EU merger control, the timing of the Commission’s review for a phase I investigation is 25 working days, and 90 working days for an in-depth review.

    Failing to notify a notifiable transaction, implementing a notified transaction in breach of the standstill obligation, implementing a prohibited transaction or circumventing or attempting to circumvent the notification requirements may be met with fines of up to 10% of aggregate turnover of the undertakings concerned in the preceding financial year. In addition, the Commission may impose fines of up to 1 % of the aggregate turnover of the undertakings concerned in the preceding financial year where they, intentionally or negligently, supply incorrect or misleading information in a notification.

    Notifications in Public Tenders

    According to the Regulation, foreign subsidies that cause or risk causing a distortion in a public procurement procedure are those that enable an economic operator to submit a tender that is unduly advantageous in relation to the works, supplies or services concerned.

    Foreign financial contributions in an EU public procurement procedure need to be notified when the following two conditions are met:

    • The estimated value of the public procurement or framework agreement net of VAT amounts to at least EUR 250 million, and
    • The economic operator (including its subsidiary companies without commercial autonomy, its holding companies, and, where applicable, its main subcontractors and suppliers involved in the same tender in the public procurement procedure) was granted aggregate financial contributions in the three financial years prior to notification of at least EUR 4 million per third country.

    Where the procurement is divided into lots, and in addition to the two conditions set out above, the value of the lot, or the aggregate value of all the lots to which the tenderer applies, needs to amount to at least EUR 125 million. Even if these thresholds are not met, participants must declare all foreign financial contributions received in the last three financial years.

    When the conditions for the notification of financial contributions as set out above are met, the economic operators participating in a public procurement procedure need to notify the contracting authority or contracting entity of all foreign financial contributions as defined in the Regulation. In all other cases, economic operators need to list in a declaration all foreign financial contributions received and confirm that the foreign financial contributions received are not notifiable in accordance with the Regulation. However, where the Commission suspects that an economic operator taking part in a public procurement procedure may have benefitted from foreign subsidies in the three years prior to the submission of the tender, or the request to participate in the public procurement procedure, it may, before the award of the contract, request the notification of the foreign financial contributions provided by third countries to that economic operator. If the Commission has requested the notification of any such financial contribution, it is deemed to be a notifiable foreign financial contribution in a public procurement procedure.

    Once the notification or declaration is submitted, the contracting authority or the contracting entity is required to transfer the notification or declaration to the Commission without delay. The Commission then has 20 working days to carry out a preliminary review. In duly justified cases, the Commission may extend this time limit by a one-time extension of 10 working days. If the Commission decides to open an in-depth investigation, it has 110 working days from the date of notification. This period may be extended only once by 20 working days, after consultation with the contracting authority or contracting entity, in justified exceptional cases. The Regulation highlights that during the preliminary review, and the in-depth investigation, all procedural steps in the public procurement procedure may continue, except for the award of the contract.

    Following the in-depth investigation, the Commission may prohibit the award of the contract, accept firm commitments offered by the economic operator or issue a “no objection” decision.

    In addition to the power to fine as described above, the Commission may impose fines of up to 1% of the aggregate turnover in the preceding year if the economic operators concerned intentionally or negligently supply incorrect or misleading information in a notification or declaration, and fines of up to 10% of their aggregate turnover in the preceding year if they fail to notify any notifiable foreign financial contributions during the public procurement procedure or circumvent or attempt to circumvent notification requirements.

    Market Investigation Tool

    Where the information available substantiates a reasonable suspicion that foreign subsidies in a particular sector, for a particular type of economic activity or based on a particular subsidy instrument, may distort the internal market, the Commission may conduct a market investigation into the particular sector, the particular type of economic activity or into the use of the subsidy instrument concerned. In the course of that market investigation, the Commission may request the undertakings or associations of undertakings concerned to supply any information deemed necessary to carry out any inspections deemed necessary. The Commission may also request Member States or the third country concerned to supply information.

    When making use of the market investigation tool, the Commission may also impose fines as described above.

    Transitional Provisions

    The FSR shall apply to foreign subsidies granted in the five years prior to the date of application of the Regulation, where such foreign subsidies distort the internal market after the start of application of this Regulation. The five-year period is limited to three in the case where foreign financial contributions were granted to an undertaking notifying a transaction, or financial contributions in the context of a public procurement procedure pursuant to the Regulation.

    The Regulation does not apply to transactions for which the agreement was concluded, the public bid announced, or a controlling interest acquired before the date of application of the Regulation, nor shall it apply to public procurement contracts that have been awarded or procedures initiated before the date of application of the Regulation.

    Making Sense of the New Regulation

    The requirements under the FSR and additional powers of the European Commission outlined above impact significantly on how companies do business within the European Union, imposing additional obligations and a requirement to be hyper-vigilant before, during and after transactions.

    Our Brussels EU Competition team is on hand to guide you through the complex regulatory landscape. We provide end-to-end antitrust and competition counsel, drawing on extensive experience working with many of the world’s top manufacturers, suppliers, distributors and service providers –many of which are household names.

    We also have first-hand experience with the industries in which our clients operate, including life sciences, chemicals, energy, food and beverages, manufacturing, technology and networks to name but a few.

    McDermott’s top-ranked global antitrust and competition practice is composed of talented colleagues throughout the United States and Europe, offering seamless multijurisdictional counsel. To clear your path and help you achieve your objectives, we deliver practical, results-oriented counsel on the full spectrum of competition issues including State aid, merger control and international trade.

    Authors
    More insights

  • Trends in Data Privacy Litigation | Q3 2022

    Trends in Data Privacy Litigation | Q3 2022

    ARTICLE / CLIENT ALERT / VIDEO

    Trends in Data Privacy Litigation | Q3 2022

    August 1, 2022

    Read time: 3 min

    Overview

    With the increased attention to and explosion of laws related to consumer privacy and cybersecurity, companies must defend their privacy practices in court and regulatory arenas now more than ever before. McDermott’s Global Privacy & Cybersecurity Practice Group is closely monitoring developments across an array of privacy-related litigations and regulatory matters. We will be providing a quarterly update regarding key privacy litigation watch outs for businesses. To contact us about anything in these updates or for your litigation needs, please contact David Saunders.

    In depth

    From derivative litigation, to NFTs, to the most anticipated BIPA decision–these were just a few privacy and cyber-related litigations that caught our attention last quarter. In the video below, Partner David Saunders explores some of these data privacy hot topics in Q3 and what organizations can expect as these cases continue.


    Video: McDermott Will & Schulte Partner David Saunders explores data privacy litigation hot topics for Q3 2022 (runtime: 3m3s)

    Conclusion

    David P. Saunders

    Partner

    Chicago

    More insights

  • Navigating Volatile Markets in the Digital Health Ecosystem

    Navigating Volatile Markets in the Digital Health Ecosystem

    ARTICLE / VIDEO

    Navigating Volatile Markets in the Digital Health Ecosystem

    August 1, 2022

    Read time: 3 min

    Overview

    The digital health market has shifted rapidly in recent months with organizations facing new pressures. Even amid increased volatility, there are ample opportunities for growth. In this new video series, McDermott’s digital health team shares timely insights and strategies to help your organization stay ahead of the curve, addressing critical areas of workforce management, financing and the potential for restructuring.

    Contact our Digital Health team if you have questions or wish to discuss how these topics may affect your company.

    What to consider


    Video: Tips & Strategies from McDermott’s 2022 Navigating Volatile Markets in the Digital Health Ecosystem programming (runtime: 3m24s)

    Stephen Bernstein, Co-Head of the Digital Health Practice, kicks off the series discussing what companies should be considering as they navigate today’s complex digital health ecosystem.

    Workforce management solutions in an uncertain economic environment

    Video: Workforce Management Solutions in an Uncertain Economic Environment, part of McDermott’s 2022 Navigating Volatile Markets in the Digital Health Ecosystem programming (runtime: 13m40s)

    McDermott partners Stephen Bernstein and Ellen Bronchetti explore timely employment considerations for digital health companies, including measures to manage and reduce risks associated with layoffs, state-by-state Worker Adjustment and Retraining Notification Act guidance, and tips for structuring compensation packages. Access the takeaways for episode one.

    Managing capitalization structures and investor relationships in today’s digital health market

    Video: Managing Capitalization Structures and Investor Relationships in Today’s Digital Health Market, part of McDermott’s 2022 Navigating Volatile Markets in the Digital Health Ecosystem programming (runtime: 12m47s)

    McDermott partners Lisa Mazur and Brian Gordon review important considerations for navigating today’s market pressures, including managing investor relationships during down rounds and incentivizing the executive management team. Access the takeaways for episode two.

    Markets under pressure strategies for restructuring and risk management

    Video: Markets Under Pressure Strategies for Restructuring and Risk Management, part of McDermott’s 2022 Navigating Volatile Markets in the Digital Health Ecosystem programming (runtime: 18m)

    McDermott partners Dale Van Demark and Felicia Perlman discuss the increased potential for broken financial covenants and restructuring in today’s market, and offer practical strategies for managing the associated risks. Access the takeaways for episode three.

    In depth
    Conclusion

    Brian M. Gordon

    Partner

    Atlanta

    Lisa Mazur

    Partner

    Chicago

    More insights